A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

NCT ID: NCT00400478

Last Updated: 2016-05-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

683 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open label, phase III study to evaluate the ability of rituximab maintenance therapy to prolong event-free survival in aggressive NHL.

Patients will be screened after successful standard induction therapy (CR or Cru following standard R-CHOP-like therapy with 8 infusions of rituximab plus CHOP-like chemotherapy (4-8 cycles). Patients will be followed until an event occurs as defined in the protocol. To evaluate the clinical efficacy of rituximab maintenance therapy as compared to observation in patients with aggressive B-cell Non-Hodgkins lymphoma or follicular lymphoma grade 3b who have achieved a complete remission after appropriate first-line therapy, measured by event-free survival (EFS), 440 patients with DLCBL or follicular NHL grade 3 (220 per arm) will be recruited.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diffuse Large B-Cell Lymphoma (DLBCL) Follicular NHL Grade 3b

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Treatment

Group Type ACTIVE_COMPARATOR

Rituximab

Intervention Type DRUG

Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)

B

Observation

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 4 to 8 cycles R-CHOP/like, total of 8x Rituximab
* CR, CRu
* ECOG/ 0.1 or 2
* Known IPI at time of diagnosis
* Age \> 18 years
* Negative pregnancy test
* Men must agree not to father a child during the therapy

Exclusion Criteria

* Transformed lymphoma
* Secondary malignancy
* Evidence of CNS - involvement
* Significant cardiac disease
* Creatinine \> 2.0 mg/dl
* HIV, Hepatitis positive
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role collaborator

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ulrich Jaeger, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Border Medical Oncology

Wodonga, Victoria, Australia

Site Status

Concord Repatriation General Hospital

Concord, , Australia

Site Status

Gosford Hospital

Gosford, , Australia

Site Status

Greenslopes Hospital

Greenslopes, , Australia

Site Status

Prince of Wales Hospital

Sydney, , Australia

Site Status

Krankenhaus Oberpullendorf

Oberpullendorf, Burgenland, Austria

Site Status

Krankenhaus Oberwart

Oberwart, Burgenland, Austria

Site Status

A.ö. Krankenhaus der Landeshauptstadt St. Pölten

Sankt Pölten, Lower Austria, Austria

Site Status

A.ö. Krankenhaus der Statutarstadt Wr. Neustadt

Wiener Neustadt, Lower Austria, Austria

Site Status

St. Johanns LK

Salzburg, Salzburg, Austria

Site Status

A.ö. Landeskrankenhaus Steyr

Steyr, Styria, Austria

Site Status

Bezirkskrankenhaus Kufstein

Endach, Tyrol, Austria

Site Status

A.oe.Bezirkskrankenhaus Hall

Hall in Tirol, Tyrol, Austria

Site Status

Universitätsklinik Innsbruck/ Klinik für Innere Medizin

Innsbruck, Tyrol, Austria

Site Status

Krankenhaus d. Barmherzigen Schwestern Linz

Linz, Upper Austria, Austria

Site Status

Krankenhaus der Elisabethinen Linz

Linz, Upper Austria, Austria

Site Status

KH Barmherzige Schwestern Ried

Ried, Upper Austria, Austria

Site Status

Klinikum Kreuzschwestern Wels GmbH

Wels, Upper Austria, Austria

Site Status

KH Barmherzige Brüder

Vienna, Vienna, Austria

Site Status

Krankenhaus der Stadt Wien Rudolfsstiftung

Vienna, Vienna, Austria

Site Status

AKH Wien / Hämatologie u. Hämostaseologie

Vienna, Vienna, Austria

Site Status

Kaiser-Franz-Josef-Spital

Vienna, Vienna, Austria

Site Status

Krankenhaus der Stadt Wien Lainz

Vienna, Vienna, Austria

Site Status

Hanusch-Krankenhaus

Vienna, Vienna, Austria

Site Status

Wilhelminenspital

Vienna, Vienna, Austria

Site Status

Sozialmedizinisches Zentrum Ost - Donauspital

Vienna, Vienna, Austria

Site Status

Landeskrankenhaus Feldkirch

Feldkirch, Vorarlberg, Austria

Site Status

LKH Bregenz

Bregenz, , Austria

Site Status

KH Dornbirn

Dornbirn, , Austria

Site Status

A.ö. Landeskrankenhaus Fürstenfeld

Fürstenfeld, , Austria

Site Status

Universitätsklinikum Graz

Graz, , Austria

Site Status

LKH Hohenems

Hohenems, , Austria

Site Status

Universitaetsklinik Innsbruck

Innsbruck, , Austria

Site Status

Landeskrankenhaus Klagenfurt

Klagenfurt, , Austria

Site Status

A.ö. Landeskrankenhaus Leoben

Leoben, , Austria

Site Status

Krankenhaus der Stadt Linz

Linz, , Austria

Site Status

LKH Weinviertel Mistelbach

Mistelbach, , Austria

Site Status

LKH Villach

Villach, , Austria

Site Status

LKH Vöcklabruck

Vöcklabruck, , Austria

Site Status

KH Waidhofen/Thaya

Waidhofen an der Thaya, , Austria

Site Status

BKH Zams

Zams, , Austria

Site Status

Clinical Centre University Sarajevo

Sarajevo, , Bosnia and Herzegovina

Site Status

University Center Tuzla

Tuzla, , Bosnia and Herzegovina

Site Status

Centro Goiano de Oncologia

Goiânia, , Brazil

Site Status

Hospital Santa Izabel

Salvador, , Brazil

Site Status

Hospital das Clinicas FMUSP

São Paulo, , Brazil

Site Status

Hospital deas Clinical FMUSP

São Paulo, , Brazil

Site Status

UMHAT "St. George" Plodviv

Plovdiv, , Bulgaria

Site Status

Nat. Centre of Hematology and Transfusiology Sofia

Sofia, , Bulgaria

Site Status

MHAT "St. Marina" Varna

Varna, , Bulgaria

Site Status

Chinese PLA General hospital

Beijing, , China

Site Status

West China Hospital of Sichuan University

Chengdu, , China

Site Status

Harbin Institue

Harbin, , China

Site Status

Jiangsu Cancer Hospital

Nanjing, , China

Site Status

Changhai Hospital

Shanghai, , China

Site Status

Shanghai Ruijin Hospital

Shanghai, , China

Site Status

Clinical Hopital Center Zagreb

Zagreb, , Croatia

Site Status

Clinical Hospital Dubrava

Zagreb, , Croatia

Site Status

Clinicall Hospital "Merkur"

Zagreb, , Croatia

Site Status

Nemocnice Boskovice s.r.o.

Boskovice, , Czechia

Site Status

Faculty Hospital Brno

Brno, , Czechia

Site Status

Univ. Hospital and Med. School Hradec Kralove

Kralove, , Czechia

Site Status

Onkologické Centrum J.G. Mendela

Novi Jicin, , Czechia

Site Status

Fakultni Nemocnice Olomouc

Olomouc, , Czechia

Site Status

Hospital Opava

Opava, , Czechia

Site Status

Fakultni nemocnice Ostrava

Ostrava-Poruba, , Czechia

Site Status

Charles University Hospital

Prague, , Czechia

Site Status

Faculty Hospital Binohrady FNKV

Prague, , Czechia

Site Status

University Hospital Motol

Prague, , Czechia

Site Status

RTO MN Usti n. Labem

Ústí nad Labem, , Czechia

Site Status

North Estonian Regional Hospital

Tallinn, , Estonia

Site Status

Tartu University Hospital

Tartu, , Estonia

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

Tuen Mun Hospital

Hong Kong, , Hong Kong

Site Status

Soroka Medical Centre

Beersheba, , Israel

Site Status

Rambam Medical Centre

Haifa, , Israel

Site Status

Rabin Medical Centre

Petah Tikva, , Israel

Site Status

Kaplan Medical Centre

Rehovot, , Israel

Site Status

Riga Hematology Center

Riga, , Latvia

Site Status

Hospital Ampang

Ampang, , Malaysia

Site Status

Hospital University Kebangsaan Malaysia

Kuala Lumpur, , Malaysia

Site Status

ISSSTE Hospital Regional de Leon

León, , Mexico

Site Status

Hospital Espanol de Mexico

Mexico City, , Mexico

Site Status

Hospital General de Mexico

Mexico City, , Mexico

Site Status

Instituto National de Cancerologia

Mexico City, , Mexico

Site Status

Hospital Regional Monterrey, ISSTE

Monterrey, , Mexico

Site Status

ISSSTEP Puebla

Puebla City, , Mexico

Site Status

Clinical Centre Skopje

Skopje, , North Macedonia

Site Status

Hospital Carlso alberto seguin escobedo Arequipa

Arequipa, , Peru

Site Status

Hospital Alberto Sabogal sooguren Callao

Callao, , Peru

Site Status

Coltea Hospital

Bucharest, , Romania

Site Status

Coltea Hospital

Bucharest, , Romania

Site Status

University Emergency Center Bucharest

Bucharest, , Romania

Site Status

Clinic Judatean de Urgenta Brasov

Târgu Mureş, , Romania

Site Status

Emergency County Clinical Hospital

Târgu Mureş, , Romania

Site Status

Belgorod regional Clinical Hospital

Belgorod, , Russia

Site Status

Moscow Regional Clinical Research Institute

Moscow, , Russia

Site Status

Botkin City Clinical Hospital

Moscow, , Russia

Site Status

Leningrad regional Cliniacal Hospital

Saint Petersburg, , Russia

Site Status

SPB Pavlov State Medical University

Saint Petersburg, , Russia

Site Status

Republican Clinic Oncology Dispensary

Ufa, , Russia

Site Status

Novgorod Regional Clinical Hospital

Veliky Novgorod, , Russia

Site Status

Clinical centre of Serbia

Belgrade, Belgrade, Serbia

Site Status

Institute of Oncology Sremska Kamenica

Kamenitz, , Serbia

Site Status

Clinical Centre Nis

Niš, , Serbia

Site Status

Clinical Centre Novi Sad

Novisad, , Serbia

Site Status

National Cancer Institut Bratislava

Bratislava, , Slovakia

Site Status

OUSA Bratislava

Bratislava, , Slovakia

Site Status

Východoslovenský onkolgický ústav

Košice, , Slovakia

Site Status

Martinská fakultná nemocnima

Martin, , Slovakia

Site Status

Institut of Oncology Ljubljana

Ljubljana, , Slovenia

Site Status

Hopelands Cancer Centre

Pietremarizburg, , South Africa

Site Status

Wilgers Oncology Centre

Pretoria, , South Africa

Site Status

Falun Hospital

Falun, , Sweden

Site Status

Sunderby Hospital

Luleå, , Sweden

Site Status

Sundsvall Hospital

Sundsvall, , Sweden

Site Status

Uddevalla Hospital

Uddevalla, , Sweden

Site Status

Kaohsiung Medical University Hospital

Kaohsiung City, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Taichung Veterans General Hospital

Taipei, , Taiwan

Site Status

King Chulalongkorn Memorial Hospital

Bangkok, , Thailand

Site Status

Phramongkutklao College of Medicine

Bangkok, , Thailand

Site Status

Ramathibodi Hospital

Bangkok, , Thailand

Site Status

Siriray Hospital

Bangkok, , Thailand

Site Status

Chiang Mai University

Chiang Mai, , Thailand

Site Status

Srinagarind Hospital

Khon Kaen, , Thailand

Site Status

Songklanagrarind Hospital

Songkhla, , Thailand

Site Status

Ankara University, School of Medicine

Ankara, , Turkey (Türkiye)

Site Status

Osmangazi Univ. school of Medicine

Eskişehir, , Turkey (Türkiye)

Site Status

Gaziantep University School of Medicine

Gaziantep, , Turkey (Türkiye)

Site Status

Ericyes Univ. Med. School

Kayseri, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Bosnia and Herzegovina Brazil Bulgaria China Croatia Czechia Estonia Hong Kong Israel Latvia Malaysia Mexico North Macedonia Peru Romania Russia Serbia Slovakia Slovenia South Africa Sweden Taiwan Thailand Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.

Reference Type RESULT
PMID: 25911553 (View on PubMed)

Jaeger U, Praxmarer M, Greil R; AGMT-NHL13 investigators. Response to comment by P. Vassilakopoulos and colleagues. Haematologica. 2015 Nov;100(11):e482. doi: 10.3324/haematol.2015.134288. No abstract available.

Reference Type RESULT
PMID: 26521299 (View on PubMed)

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Clinical Study Report

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NHL-13 (ML18223)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
NCT03731234 ACTIVE_NOT_RECRUITING PHASE2